GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Inventory-to-Revenue

Ocumension Therapeutics (HKSE:01477) Inventory-to-Revenue : 0.25 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ocumension Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2024 was HK$66.7 Mil. Ocumension Therapeutics's Revenue for the six months ended in Dec. 2024 was HK$266.6 Mil. Ocumension Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.25.

Ocumension Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 declined from Jun. 2024 (0.33) to Jun. 2024 (0.25)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ocumension Therapeutics's Days Inventory for the six months ended in Dec. 2024 was 92.11.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ocumension Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 was 1.98.


Ocumension Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for Ocumension Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Inventory-to-Revenue Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory-to-Revenue
Get a 7-Day Free Trial 0.13 0.07 0.09 0.12 0.09

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.26 0.22 0.33 0.25

Competitive Comparison of Ocumension Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, Ocumension Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's Inventory-to-Revenue falls into.


;
;

Ocumension Therapeutics Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ocumension Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (A: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )
=( (35.518 + 48.598) / 2 ) / 445.547
=42.058 / 445.547
=0.09

Ocumension Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (Q: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2024 ) + Total Inventories (Q: Dec. 2024 )) / count ) / Revenue (Q: Dec. 2024 )
=( (84.847 + 48.598) / 2 ) / 266.581
=66.7225 / 266.581
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (HKSE:01477) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ocumension Therapeutics's Days Inventory for the six months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=66.7225/132.201*365 / 2
=92.11

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ocumension Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=132.201 / 66.7225
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Liu Ye 2101 Beneficial owner
6 Dimensions Capital, L.p. 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p. 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
Alcon Pharmaceuticals Ltd 2101 Beneficial owner
Alcon Inc. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines